Investigational drug · Phase 2
ALT-100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Respiratory Distress Syndrome (ARDS).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ALT-100"
First trial start
2023
Dec 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALT-100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome (ARDS)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ALT-100" as an intervention, largest first.
- ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 TrialNot yet recruiting
University of FloridaAcademic, hospital or other
NCT07917390 · 42 participants (planned) · Start Jan 2027 · Primary completion Aug 2028
Drug: ALT-100 · For: Prostate Cancer Metastatic to Bone
Aqualung Therapeutics Corp.Industry
NCT05426746 · 32 participants · Start Jul 5, 2022 · Primary completion May 18, 2023
Drug: ALT-100 · For: ARDS, Human
Sites: Adelaide, Australia
- Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSActive, not recruiting
Aqualung Therapeutics Corp.Industry
NCT05938036 · 15 participants · Start Dec 1, 2023 · Primary completion May 1, 2027
Drug: ALT-100 mAb; ALT-100 (Placebo) · For: Acute Respiratory Distress Syndrome (ARDS)
Sites: Tucson, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- A humanized eNAMPT -neutralizing monoclonal antibody reduces cancer-induced bone pain and osteoclastogenesis in murine breast cancer model.
Mathur NC, Villaroel E, Villaroel I, et al. · Front Pain Res (Lausanne) 2026
- Clinical efficacy and multi-target mechanisms of liver-dispersing, bile-inducing, and heat-clearing TCM formulas in cholelithiasis: network meta-analysis, network pharmacology, and molecular docking study.
Cai L, Lyu Y, Li P, et al. · Front Med (Lausanne) 2026
- Early safety/therapeutic results of ALT-100 extracellular nicotinamide phosphoribosyl transferase monoclonal antibody impact in the PUERTA phase 2a acute respiratory distress syndrome trial.
Garcia JGN, Juan Guardela B, Howard C, et al. · Am J Respir Crit Care Med 2026
- Liver test pattern and histologic bile duct injury do not predict response to treatment of immunotherapy hepatotoxicity.
Rabin B, Li M, Sack JS, et al. · Hepatol Commun 2026
- [Treatment of paracetamol poisoning can be shortened].
Koppen A, Dekker D, de Lange DW, et al. · Ned Tijdschr Geneeskd 2025
- eNAMPT/TLR4 signaling drives PAH cellular phenotypic switching and lung vascular remodeling.
Ahmed M, Kee SL, Zaghloul N, et al. · Cell Commun Signal 2025
Also in development for Acute Respiratory Distress Syndrome (ARDS)
- CenthaquinePMZ-2010Phase 32 trials
Pharmazz, Inc. · Acute Respiratory Distress Syndrome (ARDS), Hypovolemic Shock
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- TISA-818-InjPhase 21 trial
EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.